PELGRAZ is a pharmaceutical agent classified as a pegylated granulocyte-colony stimulating factor (G-CSF) analog. It is primarily used to reduce the duration of neutropenia, a condition characterized by an abnormally low number of neutrophils (a type of white blood cell important for fighting infections) in the blood. This condition often arises as a side effect of chemotherapy in cancer patients. PELGRAZ works by stimulating the bone marrow to produce more neutrophils, thereby helping to prevent infections and allowing patients to continue with their chemotherapy schedule with fewer interruptions. It is administered via subcutaneous injection and is known for its extended duration of action due to the pegylation process, which enhances the molecule's stability and prolongs its activity in the body.